Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

REVELATION BIOSCIENCES, INC.

  • SAN DIEGO, California
  • Public · NASDAQ: REVB
  • 9 employees
$3.9MMarket cap
-$8.9MNet income
9Employees
REVBNASDAQ
2022IPO

About REVELATION BIOSCIENCES, INC.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$8.9M
Total assets
$11.6M
Market cap
$3.9M

Source: SEC EDGAR · updated Jun 8, 2026

NASDAQ: REVB

15-minute delayed · data by Polygon.io

Market cap
$3.9M
Open
Day range
Prev close
Volume
IPO date
Jan 11, 2022

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review REVELATION BIOSCIENCES, INC..

Write a review
Explore

Similar companies

Browse all →